On 21 April, the biopharmaceutical company AgeneBio, which develops innovative therapeutics to preserve and restore brain function, announced that it has completed enrolment in its Phase IIb clinical trial evaluating AGB101 to treat amnestic Mild Cognitive Impairment (MCI) due to Alzheimer's disease (AD). AGB101 has been developed to target the reduction of hippocampal overactivity to slow progression and delay the onset of Alzheimer’s dementia.
The Phase IIb trial, named “HOPE4MCI”, is a 78-week study, randomised, double-blind and placebo-controlled study evaluating the efficacy of AGB101 on slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in people with MCI due to AD. The study has enrolled 164 research participants across 23 sites in the United States and Canada. They will receive either AGB101 (220 mg) or placebo one daily for 78 weeks. Secondary objectives are to assess the effect of AGB101 compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE) and Functional Activities Questionnaire (FAQ). Topline results are expected in November 2022.
